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Background:  Children  are  key  drivers  of inﬂuenza  transmission.  Vaccinating  school  age  children  decreases
inﬂuenza  in  the  community.
Objective: To  pilot-test  the methods  for a future  trial  to compare  the  direct  and  indirect  beneﬁts  of
inactivated  inﬂuenza  vaccine  (IIV)  vs. live attenuated  inﬂuenza  vaccine  (LAIV)  in preventing  inﬂuenza
infection.
Methods:  During  the  2013–14  inﬂuenza  vaccination  campaign,  we  piloted  an  open-label  cluster  random-
ized  trial  involving  10 elementary  schools  in  Peterborough,  Ontario,  Canada.  We  randomized  schools  on
a 1:1  basis  to have  students  receive  IIV or LAIV.  We  invited  a subset  of vaccinated  students  and  their
households  to participate  in  a  surveillance  sub-study,  which  involved  completing  daily  symptom  diariesive vaccinesanada during  inﬂuenza  season  and  collecting  mid-turbinate  swabs  from  symptomatic  individuals  to  detect
ntario inﬂuenza  infection.  The  main  outcome  measure  was  conﬁrmed  inﬂuenza  infection  using  a  real-time
reverse  transcriptase  polymerase  chain  reaction  (PCR)  assay.
Results:  One  hundred  and  nineteen  households  (166  students  and  293  household  members)
participated.  During  15  weeks  of surveillance,  we detected  22 episodes  of PCR-conﬁrmed
inﬂuenza  (21  inﬂuenza  A/H1N1  and 1  inﬂuenza  B).  The  incidence  of  inﬂuenza  per  1000
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person-days  was  1.24 (95%  CI, 0.40–2.89)  for IIV-vaccinated  students,  compared  to 0.13  (95%  CI,
0.003–0.72)  for LAIV-vaccinated  students;  the  incidence  rate ratio  was  0.10  (95% CI, 0.002–0.94).  Sim-
ilarly,  the incidence  of  inﬂuenza  per  1000  person-days  was  1.33  (95%  CI, 0.64–2.44)  for  IIV household
members,  compared  to  0.47  (95%  CI, 0.17–1.03)  for  LAIV  household  members;  the  incidence  rate  ratio  was
0.36  (95%  CI,  0.11–1.08).  The  overall  incidence  rate ratio (combining  students  and  household  members)
was 0.27  (95%  CI,  0.09–0.69).
Conclusions:  Household  surveillance  involving  participant  monitoring  and  reporting  of  symptoms  and
self-collection  of  mid-turbinate  swabs  is feasible.  A larger  study  is required  to  validate  the  suggestion
that  vaccinating  children  with  LAIV  might  confer  more protection  against  inﬂuenza  for  both  children  and
their household  contacts,  compared  to  IIV.
Trial registration:  ClinicalTrials.gov  NCT01995851.
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. Introduction
School children drive inﬂuenza epidemics through virus trans-
ission to their contacts [1–4]. Mathematical models and ﬁeld
esearch suggest that vaccinating school children provides indi-
ect protection (herd immunity) to both household members and
he community at large [5–9], thereby reducing the burden of
nﬂuenza. However, inﬂuenza vaccine coverage in children is sub-
ptimal for various reasons, including accessibility, competing
emands, and fear of needles among children [10–12].
An alternative to injectable inactivated inﬂuenza vaccine (IIV) is
he intranasal, live attenuated inﬂuenza vaccine (LAIV). LAIV was
rst approved for use in the United States in 2003 for individuals
ged 5–49 years, and extended to those aged 2–49 years in 2007
13]. In Canada, LAIV was approved for use in June 2010, and for the
011–12 to 2013–14 inﬂuenza seasons Canada’s National Advisory
ommittee on Immunization preferentially recommended it over
IV for healthy children aged 2–17 years based on efﬁcacy, effective-
ess, and immunogenicity [14–17]. However, the extent of indirect
rotection from LAIV for reducing the incidence of laboratory-
onﬁrmed inﬂuenza among household contacts has not yet been
stablished.
In the fall of 2013, we piloted a cluster randomized trial to evalu-
te administering LAIV vs. IIV to children at school-based inﬂuenza
mmunization clinics. A cluster design was used because the inter-
ention was at the level of the school. This paper describes a nested
ub-study involving students who were vaccinated as part of the
arger study. We  conducted surveillance of the vaccinated students
nd their households for inﬂuenza infection in order to assess fea-
ibility of study procedures and generate parameter estimates to
nform a full-scale trial evaluating the direct and indirect beneﬁts
f LAIV.
. Methods
We  conducted an open-label cluster randomized trial involv-
ng 10 elementary schools within the geographic boundaries of
he Peterborough County-City Public Health Unit (PCCHU) dur-
ng the 2013–14 inﬂuenza vaccination campaign. PCCHU is the
ocal public health department that serves a mixed urban-rural
ommunity 125 km northeast of Toronto, Ontario. Out of the 28
chools belonging to the Kawartha Pine Ridge District School Board,
0 agreed to participate. Using a standard computer pseudoran-
om number generator, researcher JAP randomized the schools
n a 1:1 basis to having students between Junior Kindergarten
age 4) and Grade 8 (age 13) offered free LAIV (FluMist®) or IIV
Vaxigrip®) at PCCHU-organized school-based immunization clin-
cs between 11 and 22 November 2013. Both vaccines contained
/California/7/2009 (H1N1) X-179A, A/Texas/50/2012 (H3N2) X-
23A, and B/Massachusetts/2/2012 (Yamagata lineage) BX-51B
iruses. Details are described elsewhere [18].hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
We invited 320 households (with 429 school-vaccinated stu-
dents from 9 of the 10 schools to participate in this study).
One IIV-assigned school, representing 11 households with 20
vaccinated students, was  excluded from the study due to distance
from the city of Peterborough and the related challenges of reaching
them for follow-up in the winter. The study involved monitor-
ing for acute respiratory symptoms among all household members
and collecting specimens from symptomatic participants to test for
inﬂuenza during the period of local inﬂuenza activity.
2.1. Recruitment
Between 6 December 2013 and 1 February 2014, research assis-
tants attempted to contact each vaccinated student’s parent(s) by
telephone to participate. Repeated calls were made to those who
could not be reached, until the end of the recruitment period. We
limited recruitment from each school to a maximum of 25 house-
holds. A research assistant visited interested households to obtain
written consent from each adult (aged ≥16 years) in the family and
assent from each child younger than 16 years. Households were
offered an incentive of a $25 Amazon.ca gift card per participant.
2.2. Study procedures
Once consent/assent was obtained for the household, a research
assistant recorded baseline data from each household member,
including demographics, risk factors for inﬂuenza complications,
and current inﬂuenza vaccination status. We  provided each house-
hold with either paper or electronic diaries (via a link to an
Internet-based questionnaire) for recording daily symptoms, a dig-
ital thermometer, Copan ﬂocked nasal swabs, and training on the
collection of mid-turbinate swabs from oneself or other household
members.
We instructed participating households to complete the daily
diary to record whether any household member had acute respi-
ratory symptoms, illness history (e.g., hospitalizations related to
lower respiratory tract infections and pneumonia, physician vis-
its for respiratory illness), and missed days of school or work due
to acute respiratory infections. If any household member exhib-
ited any one of cough, sore throat, or fever, or at least two other
symptoms (runny nose, headache, sinus problems, muscle aches,
fatigue/very tired, ear ache, ear infection, chills, and sneezing), they
were to collect a mid-turbinate swab on themselves (or parents
would swab children) as soon as symptoms appeared (within 48 h),
and to call a research assistant to collect a second mid-turbinate
swab. Thus there were typically two swabs per episode of illness,
so that we  could compare participant collection with research assis-
tant collection. A participant was  considered to have had a positive
test if either of the two  specimens was  positive for inﬂuenza. A
repeat swab was collected 7 days after the collection of the ini-
tial swab (indicating a new episode) if the individual had at least
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examined children younger than nine years of age, IIV-vaccinated
students were less likely to have been vaccinated against inﬂuenza
during the 2012–13 season compared to LAIV-vaccinated students
(25.9 vs. 41.3%). However, parents of IIV-vaccinated students were
Assessed for eligibility 
 (28 schools ) 
Excluded:   
Refused to participate (18 schools) 
Rand omize d (10 scho ols) 
Alloc ated  to IIV 
(5 schools, mean  school  size = 
278.8  stud ents , variance  of 
school  size  = 11,0 05.8) 
Received  allocated  inte rvention 
(5 school) 
Did not recei ve alloca ted 
interven tion  (0 sc hools) 
A
ll
o
ca
ti
o
n
 
E
n
ro
ll
m
en
t
Allocate d to  LAIV 
(5 schoo ls, mean scho ol size  = 
291.6 stu dents, va riance  of 
school size  = 17,519.4 ) 
Received allo cated  intervent ion 
(5 schoo ls) 
Did not rece ive  al locate d 
intervention (0 scho ols )  
R
ec
ru
it
m
en
t 150 children  vaccina ted  from 
118 hou sehol ds from 4 
schools  
Exclud ed 1 school from 
study because  of remotenes s  
279 ch ildren vacc inate d from 20 2 
households from 5 schools 
Excluded 0 schoo ls 
House hold response  rate   
(44/118  hous eholds;  37% )
House hold response  rate   
(78/202  hous eholds;  39% )
Lost to follow  up 
 (2  househo lds ; with drew after 
a week, no longer  in terested)
Los t to follow up 
 (1 ho usehold;  withdrew  after 
a wee k, no  lo nger interested) 
F
o
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o
w
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p
42 ho usehol ds from 4 schools 77 house holds  from 5 scho ols is
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ne additional symptom, as well as the initial two symptoms; or if
he individual had at least two new symptoms (different from the
nitial two symptoms and the ﬁrst two had resolved).
Data collection began on 16 December 2013, when the weekly
ercentage of clinical and public health laboratory tests positive for
nﬂuenza from PCCHU and the three adjacent health departments
Durham Region Health Department, Hastings and Prince Edward
ounties Health Unit, and Haliburton, Kawartha, Pine Ridge District
ealth Unit) exceeded 5%. The surveillance period continued for 15
eeks, ending on 24 March 2014.
During the surveillance period, research assistants contacted
ach household that opted for paper diaries twice weekly by tele-
hone to obtain data for each household member, and recorded this
nformation directly into the survey software program FluidSur-
eys (Ottawa, Canada). Households that opted for electronic diaries
eceived a daily link to the patient diary. We  emailed the main con-
act of each household, who completed the form on behalf of all
ousehold members. If no entries were submitted for a household
or three consecutive days, we called to remind them to complete
he diary.
The research assistants collected all nasal swabs during house-
old visits and brought them to the regional laboratory in
eterborough, where they were stored in a refrigerator until they
ere shipped by courier at refrigeration temperature to the central
ublic Health Ontario laboratory in Toronto for testing. The spec-
mens were tested by real-time reverse transcription polymerase
hain reaction (rRT-PCR) using protocols from the U.S. Centers for
isease Control and Prevention (CDC) to detect the presence of
nﬂuenza A (M gene) or B (NS1 gene) virus. Subtyping for seasonal
nﬂuenza A/H3 was performed by real-time RT-PCR targeting the
A gene (CDC protocol) and A(H1N1)pdm09 was conﬁrmed using
n in-house real-time RT-PCR assay [19].
.3. Data analysis
We  calculated inﬂuenza incidence per 1000 person-days
mong vaccinated students and household members by count-
ng laboratory-conﬁrmed infections as the numerator, while the
enominator was the number of uninfected person-days, and we
sed the Poisson distribution to estimate the conﬁdence intervals.
e did not explicitly exclude the ﬁrst 14 days following vaccina-
ion, but the enrolment of most participants occurred more than
4 days following receipt of inﬂuenza vaccine. We computed inci-
ence rate ratios comparing inﬂuenza infection between the two
ntervention arms, both overall and separately for students and
ousehold members.
Because the recruitment of many LAIV households took place
ater than the recruitment of most IIV households (mainly because
he research assistants recruited school by school, and inadver-
ently processed the IIV schools ﬁrst), we measured the number
f unobserved days, expressed as the difference between the date
f vaccination and the ﬁrst date of observation. We  also compared
he proportion of symptomatic participants who  were swabbed
nd the proportion of swabbed participants who  were symp-
omatic to determine if there were any differences across the
wo arms. To assess the validity of self-collected mid-turbinate
wabs, we compared the results of the mid-turbinate specimens
ollected by participants with those collected by the research
ssistants. Lastly, we compared characteristics of individuals who
ested positive for inﬂuenza with those who tested negative for
nﬂuenza.
Statistical signiﬁcance was determined at the 95% level using
wo-tailed tests. We  used STATA version 10.0 (2007, StataCorp, LP,
ollege Station, TX, USA) to analyze the data.3 (2015) 4910–4915
2.4. Ethics
This study was  approved by Public Health Ontario’s Ethics
Research Board and the Kawartha Pine Ridge District School Board’s
Research Advisory Committee.
3. Results
One hundred and twenty-two households agreed to partici-
pate. Three households withdrew from the study within one week
of enrolment. In total, we analyzed data from 119 households
(166 students and 293 household members), including 42 house-
holds (57 students and 108 household members) with a student
who received IIV at school (“IIV households”), and 77 households
(109 students and 185 household members) with a student who
received LAIV at school (“LAIV households”) (Fig. 1). The mean num-
ber of household members was 3.9 for IIV households and 3.8 for
LAIV households.
Students from both groups were similar in age, sex, body mass
index, and risk factors for inﬂuenza complications. However, a
lower percentage of IIV-vaccinated students had received inﬂuenza
vaccination the previous season (2012–13) compared to LAIV-
vaccinated students (32.4 vs. 51.6%; p = 0.02) (Table 1). When weincl uded  in pr imar y anal ysis 
(57  students, 108 ho useho ld 
members)
included  in  pri mar y ana lysis 
(109  st udents,  185  house hold 
members)A
n
a
ly
s
Fig. 1. Diagram showing the ﬂow of schools through the cluster randomized trial.
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Table  1
Baseline characteristics of the study population.
Students Household members
Characteristic IIVa n = 57 (%) LAIVb n = 109 (%) IIV n = 108 (%) LAIV n = 185 (%)
Mean age (SE) 8.17 (0.4) 8.19 (0.3) 33.3 (1.8) 31.78 (1.2)
Age  groups
≤3 years – – 16 (14.8) 19 (10.3)
4–5  years 12 (21.1) 20 (18.3) 0 (0) 4 (2.2)
6–11  years 35 (61.4) 73 (67.0) 4 (3.7) 9 (4.9)
12–13  years 10 (17.5) 16 (14.7) 1 (1.0) 4 (2.2)
14–17  years – – 7 (6.5) 11 (6.0)
18–39  years – – 30 (27.8) 71 (38.4)
40–64 years – – 46 (42.6) 64 (34.6)
≥65  years – – 4 (3.7) 3 (1.6)
Female sex 31 (54.4) 52 (47.7) 60 (55.6) 97 (52.4)
Education
Less  than high school – – 14 (13.0) 19 (10.3)
High  school graduation – – 37 (34.3) 52 (28.1)
Post-secondary education – – 57 (52.8) 114 (61.6)
Body mass indexc
Underweight (<18.5) – – 17 (15.7) 32 (17.3)
Normal (18.5–24.9) 45 (79.0) 84 (77.1) 43 (39.8) 46 (24.9)
Overweight (25.0–29.9) 6 (10.5) 17 (15.6) 27 (25.0) 68 (36.8)
Obese (≥30.0) 6 (10.5) 8 (7.3) 21 (19.4) 39 (21.1)
Risk  factors for inﬂuenza complications
Chronic diseasesd 1 (1.8) 8 (7.3) 23 (21.3) 31 (16.8)
Weakened immune system 0 (0) 0 (0) 3 (2.8) 3 (1.6)
Long-term user of aspirin 0 (0) 0 (0) 5 (4.6) 10 (5.4)
Aboriginal status 3 (5.6) 8 (7.3) 1 (0.9) 11 (6.0)
Healthcare worker – – 9 (9.3) 22 (13.3)
Smoker – – 14 (13.0) 19 (10.3)
Pregnant (females only) – – 1 (0.9) 2 (1.1)
Has  a regular doctor 55 (96.5) 102 (93.6) 102 (94.4) 169 (91.4)
Vaccinated against inﬂuenza, 2012–13 season 12 (32.4) 47 (51.6) 40 (40.4) 77 (45.3)
Vaccinated against inﬂuenza since October 2013 57 (100) 109 (100) 38 (35.2) 83 (44.9)
a Inactivated inﬂuenza vaccine; b Live attenuated inﬂuenza vaccine; c Categories for children are based on the 2000 Centers for Disease Control and Prevention Growth
Reference in the United States; d,f Chronic diseases included: asthma, diabetes, cancer, anemia, heart disease, lung disease, kidney disease, blood diseases; and n (denominator)
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df  each response varies depending on completeness of data, missing data were excl
ore likely than parents of LAIV-vaccinated students to report their
hild’s vaccination status for the 2012–13 season as “unknown”
38.7 vs. 12.7%).
Household members from both groups were similar except
or a trend toward fewer members of IIV households having been
accinated against inﬂuenza during the 2013–14 season compared
o members of LAIV households (35.2 vs. 44.9%; p = 0.10).
We detected 22 episodes of PCR-conﬁrmed inﬂuenza dur-
ng the study period (21 inﬂuenza A/H1N1 and 1 inﬂuenza B).
ne household had 3 cases, 4 households had 2 cases, and 11
ouseholds had a single case. We  observed 15 episodes of PCR-
onﬁrmed inﬂuenza in IIV households compared to 7 episodes in
AIV households (Table 2). The incidence of inﬂuenza per 1000
erson-days was 1.24 (95% CI, 0.40–2.89) for IIV-vaccinated stu-
ents, compared to 0.13 (95% CI, 0.003–0.72) for LAIV-vaccinated
tudents; the incidence rate ratio was 0.10 (95% CI, 0.002–0.94).
imilarly, the incidence of inﬂuenza per 1000 person-days was
.33 (95% CI, 0.64–2.44) for IIV household members, compared to
.47 (95% CI, 0.17–1.03) for LAIV household members; the inci-
ence rate ratio was 0.36 (95% CI, 0.11–1.08). The overall incidence
ate ratio (combining students and household members) was 0.27
95% CI, 0.09–0.69). The intra-class correlation within schools was
.07.
IIV households had signiﬁcantly fewer unobserved days at the
tart of the surveillance period compared to LAIV households (41.7
s. 46.3 days, respectively; p = 0.001). We  observed no differences
etween the IIV and LAIV groups in terms of the proportion of symp-
omatic participants who were swabbed (68.2 vs. 73.9%; p = 0.31),
r the proportion of swabbed individuals who fulﬁlled the case
eﬁnition (98.4 vs. 99.6%; p = 0.38).from the analysis.
The mean duration between participant collection and research
assistant swab collection was 1.6 days (range 0–7 days; stan-
dard deviation 1.34 days), with 83% of research assistant swabs
collected within 2 days of participant swabs. Of  the 22 episodes
of documented inﬂuenza infection, no swab was  collected by a
research assistant for 4 episodes. Of the remaining 18 episodes, we
observed concordance between the 2 swabs for 12 episodes (with
a mean delay between participant collection and research assis-
tant collection of 0.75 days, range 0–2 days), and discordance for
6 episodes (with mean delay of 2 days, range 0–4 days). Among
the discordant episodes, 4 episodes were detected only by the
participant and 2 episodes were detected only by the research
assistant. If the study had involved only swab collection by partici-
pants, we would have detected 90.9% of the total inﬂuenza episodes
(20/22).
The inﬂuenza test-positive and test-negative participants were
similar, except that the former group was signiﬁcantly less likely to
have been vaccinated against inﬂuenza (with either vaccine) during
the 2013–14 season (4.5 vs. 27.4%; p = 0.02) or the 2012–13 season
(4.5 vs. 40.2%; p < 0.001) (Table 3).
4. Discussion
This pilot study was conducted to assess the feasibility of study
procedures and to generate parameter estimates to inform a future
full-scale trial comparing the direct and indirect beneﬁts of immu-
nizing children against inﬂuenza with LAIV compared with IIV. We
demonstrated that a surveillance study involving vaccinated stu-
dents and their household members monitoring for symptoms,
reporting using daily diaries, and self-collecting mid-turbinate
4914 J.C. Kwong et al. / Vaccine 33 (2015) 4910–4915
Table 2
Incidence rates and incidence rate ratios of laboratory-conﬁrmed inﬂuenza.
Students Household members Combined
IIVa n = 57 LAIVb n = 109 IIV n = 108 LAIV n = 185 IIV n = 165 LAIV n = 294
Number of inﬂuenza infections (%) 5 (8.8) 1 (0.9) 10 (9.3) 6 (3.2) 15 (9.1) 7 (2.4)
Uninfected person-days of follow-up 4044 7715 7541 12,683 11,585 20,398
Incidence of inﬂuenza per 1000
person-daysc (95% CI)
1.24 (0.40–2.89) 0.13 (0.003–0.72) 1.33 (0.64–2.44) 0.47 (0.17–1.03) 1.29 (0.73–2.14) 0.34 (0.14–0.71)
Incidence rate ratio (LAIV/IIV) (95% CI) 0.10 (0.002–0.94) 
a Inactivated inﬂuenza vaccine; b Live attenuated inﬂuenza vaccine; and c Number of la
Table 3
Characteristics of those who  tested positive for inﬂuenza compared to those who
tested negative for inﬂuenza.
Characteristic Inﬂuenza positives
n = 22 (%)
Inﬂuenza negatives
n  = 437 (%)
Students 6 (27.3) 160 (36.5)
Household members 16 (72.7) 278 (63.5)
Age groups
≤3 years 3 (13.6) 33 (7.5)
4–13 years 7 (31.8) 181 (41.3)
14–17 years 3 (13.6) 15 (3.4)
18–39 years 3 (13.6) 99 (22.6)
40–64 years 6 (27.3) 103 (23.5)
≥65 years 0 (0) 7 (1.6)
Female sex 11 (50.0) 22 (52.3)
Education
Less than high school 13 (59.1) 242 (55.3)
High school graduation 2 (9.1) 31 (7.1)
Post-secondary education 7 (31.8) 165 (37.7)
Body mass indexa
Underweight (<18.5) 0 (0) 49 (11.2)
Normal (18.5–24.9) 13 (59.1) 196 (44.7)
Overweight (25.0–29.9) 5 (22.7) 76 (17.4)
Obese (≥30.0) 4 (18.2) 117 (26.7)
Risk factors for inﬂuenza
complications
Chronic diseasesb 3 (13.6) 60 (13.7)
Aboriginal status 1 (4.5) 22 (5.0)
Healthcare worker 1 (4.5) 30 (6.9)
Has a regular doctor 21 (95.5) 407 (92.9)
Vaccinated against inﬂuenza,
2012–13 season
1 (6.3) 176 (40.3)
Vaccinated against inﬂuenza since
October 2013
1 (4.5) 120 (27.4)
a Categories for children are based on the 2000 Centers for Disease Control and
Prevention Growth Reference in the United States; b Chronic diseases included:
a
b
s
g
p
v
A
d
r
b
i
O
L
b
s
d
r
r
m
Rsthma, diabetes, cancer, anemia, heart disease, lung disease, kidney disease, and
lood diseases; some categories were excluded if they were 0% (e.g., aspirin user).
wabs within 48 h is feasible. Interestingly, our results provide sug-
estive evidence of direct beneﬁts that are greater than have been
reviously estimated, as well as possible indirect protection from
accinating school children with LAIV rather than IIV.
The direct beneﬁts of LAIV vs. IIV in children are well established.
 meta-analysis of 3 clinical trials involving 13,000 healthy chil-
ren aged 6 months to 17 years demonstrated that compared to IIV,
eceipt of LAIV reduced the risk of laboratory-conﬁrmed inﬂuenza
y 45–53% in vaccine-naïve children (aged 6–71 months) and 35%
n previously vaccinated older children (aged 6–17 years) [17].
ur study suggested a 90% reduction in inﬂuenza incidence among
AIV-vaccinated children compared with IIV-vaccinated children,
ut the conﬁdence interval was very wide due to the small sample
ize.
The indirect beneﬁts of IIV have been demonstrated most
eﬁnitively to date in a cluster randomized trial of rural Hutterite
eligious communities [6]. Vaccinating 83% of school age children
educed the risk of inﬂuenza infection among other community
embers (who were generally not vaccinated) by 61%. An earlier
CT demonstrated that household contacts of IIV-vaccinated0.36 (0.11–1.08) 0.27 (0.09–0.69)
boratory-conﬁrmed inﬂuenza infections/1000 uninfected person-days.
pre-school aged children were less likely to experience febrile
respiratory illnesses [20]. Further, observational studies that have
examined the impact of immunizing children have found that
this resulted in signiﬁcant reductions in episodes of inﬂuenza-like
illnesses and inﬂuenza-related complications in the elderly and
adult populations [21–23].
Whether LAIV confers greater indirect beneﬁts than IIV remains
uncertain. Piedra et al. conducted a nonrandomized community-
based inﬂuenza vaccine trial of both vaccines during the 2003–04
season and found that only certain age groups (adults aged 35–44
years and children aged 5–11 years) experienced lower rates of
medically-attended acute respiratory illness during the epidemic
in the intervention vs. control community, based on a coverage of
32% [23]. They did not assess the indirect beneﬁts in a head-to-head
comparison. The results of our study suggest that household mem-
bers of LAIV-vaccinated children were 64% less likely to experience
inﬂuenza infection than household members of IIV-vaccinated
children, although once again the conﬁdence interval was very
wide.
Strengths of this study include the rigorous follow-up with daily
symptom monitoring, the use of PCR-conﬁrmed inﬂuenza as the
outcome, and the use of local viral surveillance data to determine
the surveillance period.
This study had a number of limitations. First, this was an
open-label trial, which may  have introduced bias because both
participants and research staff were aware of the type of vaccine
received by the students. However, the proportion of symptomatic
participants who  were swabbed and the proportion of swabbed
individuals who  fulﬁlled the case deﬁnition were comparable
across both groups (although a slightly higher proportion of symp-
tomatic participants in the LAIV group was  swabbed), suggesting
that knowledge of vaccine type did not substantially inﬂuence the
likelihood of specimen collection. Second, the relatively low partic-
ipation rate of the households may have introduced selection bias
and impacted generalizability of the ﬁndings, but the participation
rate was  similar across the two  arms. Third, due to the brief interval
between the school immunization clinics and the start of inﬂuenza
season, household recruitment continued for the ﬁrst 7 weeks of
the surveillance period, and we  noted a greater degree of delay in
recruiting LAIV households than IIV households. As most of the IIV
households enrolled prior to the peak of inﬂuenza activity whereas
the majority of the LAIV households enrolled following the peak,
and consequently a greater proportion of swabbing episodes for
the IIV group occurred earlier than the LAIV group, we may  have
incompletely captured inﬂuenza infections among the LAIV house-
holds, thereby leading to biased estimates of vaccine effectiveness.
Fourth, incomplete ascertainment of inﬂuenza infections may  have
occurred due to participant fatigue, refusal to be swabbed (partic-
ularly in young children), or suboptimal identiﬁcation of inﬂuenza
infection among infants using the provided symptom list (e.g., irri-
tability was not included on the list). However, each of these issues
should have affected both arms equally. Fifth, we  stopped the study
early and missed an inﬂuenza B outbreak that occurred over the
course of 10 weeks (24 March 2014–31 May  2014) following the
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[23] Piedra PA, Gaglani MJ,  Kozinetz CA, Herschler GB, Fewlass C, Harvey D, et al.J.C. Kwong et al. / Vac
nd of this study. Sixth, this study was intended to be a pilot,
o the small sample size precluded adjustment for any potential
onfounders. Seventh, changes in household members’ inﬂuenza
accination status may  not have been reported, which could have
ntroduced misclassiﬁcation bias. Finally, since we observed a trend
oward higher IIV coverage among LAIV household members, it
ay  not be possible to determine whether the reduced incidence
f inﬂuenza in LAIV household members is attributable to indirect
rotection from vaccinating students with LAIV or direct protection
rom receipt of IIV among household members.
A future study would be strengthened by incorporating the fol-
owing features: (1) incorporating blinding of both participants and
nvestigators by using suitable placebos (i.e., saline nasal sprays for
hose assigned to IIV, and saline intramuscular injections for those
ssigned to LAIV); (2) scheduling vaccination clinics as early as pos-
ible to minimize vaccinations occurring in non-school settings;
3) optimizing strategies to recruit households into the study; and
4) using other data sources to ascertain inﬂuenza vaccination sta-
us over the course of the inﬂuenza season to mitigate incomplete
eporting by participants.
. Conclusion
The results of our pilot study demonstrate that a household
urveillance study involving participant monitoring and reporting
f symptoms and self-collection of mid-turbinate swabs is feasible.
 larger study is required to validate the suggestion that vaccinating
hildren with LAIV might confer more protection against inﬂuenza
or both children and their household contacts, compared to IIV.
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